Guidant says third-quarter revenues will miss forecasts
This article was originally published in Clinica
Executive Summary
Guidant has warned that its third-quarter sales will be below analysts' expectations by some $45 million, due in part to the falling euro, but mainly due to lower coronary stent sales. Guidant's shares dropped 19% to around $56 on the warning, despite the simultaneous announcement of FDA approval for the MULTI-LINK TETRA stent.